AIM2 Antibody - #DF3514

(5)   (6)  
Product: AIM2 Antibody
Catalog: DF3514
Description: Rabbit polyclonal antibody to AIM2
Application: WB IF/ICC
Reactivity: Human, Mouse
Prediction: Horse
Mol.Wt.: 39 KD; 39kD(Calculated).
Uniprot: O14862
RRID: AB_2835876

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Horse(88%)
Clonality:
Polyclonal
Specificity:
AIM2 Antibody detects endogenous levels of total AIM2.
RRID:
AB_2835876
Cite Format: Affinity Biosciences Cat# DF3514, RRID:AB_2835876.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Absent in melanoma 2; AIM 2; Aim2; AIM2_HUMAN; Interferon-inducible protein AIM2; OTTHUMP00000035296; PYHIN4;

Immunogens

Immunogen:
Uniprot:

O14862(AIM2_HUMAN) >>Visit HPA database.

Gene(ID):
AIM2(9447)
Expression:
O14862 AIM2_HUMAN:

Expressed in spleen, small intestine, peripheral blood leukocytes, and testis.

Sequence:
MESKYKEILLLTGLDNITDEELDRFKFFLSDEFNIATGKLHTANRIQVATLMIQNAGAVSAVMKTIRIFQKLNYMLLAKRLQEEKEKVDKQYKSVTKPKPLSQAEMSPAASAAIRNDVAKQRAAPKVSPHVKPEQKQMVAQQESIREGFQKRCLPVMVLKAKKPFTFETQEGKQEMFHATVATEKEFFFVKVFNTLLKDKFIPKRIIIIARYYRHSGFLEVNSASRVLDAESDQKVNVPLNIIRKAGETPKINTLQTQPLGTIVNGLFVVQKVTEKKKNILFDLSDNTGKMEVLGVRNEDTMKCKEGDKVRLTFFTLSKNGEKLQLTSGVHSTIKVIKAKKKT

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
88
Pig
0
Bovine
0
Sheep
0
Dog
0
Xenopus
0
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O14862 As Substrate

Site PTM Type Enzyme
K39 Ubiquitination
K64 Methylation
K71 Acetylation
K79 Acetylation
K85 Acetylation
K160 Acetylation
K235 Ubiquitination
T254 Phosphorylation
T257 Phosphorylation
T262 Phosphorylation
S332 Phosphorylation

Research Backgrounds

Function:

Involved in innate immune response by recognizing cytosolic double-stranded DNA and inducing caspase-1-activating inflammasome formation in macrophages. Upon binding to DNA is thought to undergo oligomerization and to associate with PYCARD initiating the recruitment of caspase-1 precusrsor and processing of interleukin-1 beta and interleukin-18. Detects cytosolic dsDNA of viral and bacterial origin in a non-sequence-specific manner. Can also trigger PYCARD-dependent, caspase-1-independent cell death that involves caspase-8 (By similarity). Tumor suppressor which may act by repressing NF-kappa-B transcriptional activity.

Subcellular Location:

Nucleus. Cytoplasm.
Note: Activated inflammasomes can aggregate in the cytosol as speck-like particles.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in spleen, small intestine, peripheral blood leukocytes, and testis.

Subunit Structure:

Self-associates; forms homooligomers in response to cytosolic dsDNA and the dsDNA seems to serve as oligomerization platform. Component of the AIM2 inflammasome. Interacts with PYCARD, IFI16, EIF2AK2/PKR and MAPRE1. Interacts with PYDC5; disrupts assembly of the ALR inflammasome complex.

Family&Domains:

The pyrin domain mediates homotypic interaction with PYCARD (PubMed:19158676, PubMed:19158675).

The HIN-20 domain mediates dsDNA binding via electrostatic interactions.

Belongs to the HIN-200 family.

Research Fields

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway.   (View pathway)

References

1). Roxadustat (FG-4592) protects against ischemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation Get access Arrow. Nephrology Dialysis Transplantation (PubMed: 36413468) [IF=6.1]
2). Ozanimod-dependent activation of SIRT3/NF-κb/AIM2 pathway attenuates secondary injury after intracerebral hemorrhage. Molecular Neurobiology (PubMed: 36417102) [IF=5.1]
3). Ginsenoside Rg1 Inhibits Microglia Pyroptosis Induced by Lipopolysaccharide Through Regulating STAT3 Signaling. Journal of Inflammation Research (PubMed: 34908862) [IF=4.5]

Application: WB    Species: Mice    Sample: BV-2 cells

Figure 4 Rg1 inhibits pyroptosis through STAT3 signaling. (A) Conserved sequences at binding sites of STAT3. (B) STAT3 binding sites on AIM2 promoters predicted by JASPAR. (C) The binding relationship between STAT3 and AIM2 promoter verified by ChIP-qPCR experiment. *p < 0.05 compared with IgG negative control. (D) Western blotting analysis showing NLRP3, ASC, AIM2, cleaved-caspase-1, pro-caspase-1, IL-1β, mature-IL-1β, GSDMD and GSDMD-N protein expression in BV-2 cells with or without Rg1 pretreatment exposed to LPS or LPS with IL-6 stimulation, and with or without stattic treatment induced by LPS. (E–M) Bar graph shows gray value analysis based on immunoblot images. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control, #p < 0.05 and ###p < 0.001 compared with LPS treatment group, ∆p < 0.05 and ∆∆∆p < 0.001 compared with LPS+Rg1 treatment group. (N) Flow cytometry shows the percentage of dead cells over total cells in each stage. The effect of Rg1 (60μM) in down-regulating the rate of apoptotic cells induced by LPS was abrogated by IL-6. Compared with LPS (2μg/mL) treatment group, the rate of apoptotic cells was markedly decreased in stattic and LPS co-incubated group. (O) Bar graph shows the statistical results of the rate of dead cells in each group. **p < 0.01 compared with control, ##p < 0.01 compared with LPS treatment group, ∆∆p < 0.01 compared with LPS+Rg1 treatment group.
4). Calpain Inhibitor Calpeptin Alleviates Ischemia/Reperfusion-Induced Acute Kidney Injury via Suppressing AIM2 Inflammasome and Upregulating Klotho Protein. Frontiers in Medicine (PubMed: 35155498) [IF=3.9]

Application: WB    Species: Mouse    Sample: kidney issues

Figure 3 Calpeptin inhibits AIM2 and NLRP3 inflammasome-mediated inflammation, and upregulates Klotho protein expression in IR mouse model. (A) Western blotting of Calpain 1, Calpain 2, Klotho, AIM2, NLRP3, pro-Caspase 1, cleaved-Caspase 1, IL-1β and IL-18 in the kidney of all mice. (B) Quantitative determination of Calpain 1, Calpain 2, Klotho, AIM2, NLRP3, cleaved-Caspase 1 and IL-18. (C) The mRNA levels of Calpain 2, Klotho, AIM2, ASC and GSDMD in the kidney among different groups. (D) The calpain activity of renal issues was measured by the relative fluorescence units (400/505 nm). (E) The cathepsin B activity of kidney issues was tested by the relative fluorescence units (400/505 nm). (F) Representative immunohistochemical micrographs from the kidney issues of different groups stained with Calpain 1, Calpain 2 and AIM2. ×400, bar = 50 μm. All data were presented as mean ± SEM (n = 3). NS, no significance; *p < 0.05 vs. sham group; **p < 0.01 vs. sham group; ***p < 0.001 vs. sham group; #p < 0.05 vs. IR group; ##p < 0.01 vs. IR group; ###p < 0.001 vs. IR group. CP, calpeptin; IR, ischemia/reperfusion; RFU, relative fluorescence units.

Application: IHC    Species: Mouse    Sample: kidney issues

Figure 3 Calpeptin inhibits AIM2 and NLRP3 inflammasome-mediated inflammation, and upregulates Klotho protein expression in IR mouse model. (A) Western blotting of Calpain 1, Calpain 2, Klotho, AIM2, NLRP3, pro-Caspase 1, cleaved-Caspase 1, IL-1β and IL-18 in the kidney of all mice. (B) Quantitative determination of Calpain 1, Calpain 2, Klotho, AIM2, NLRP3, cleaved-Caspase 1 and IL-18. (C) The mRNA levels of Calpain 2, Klotho, AIM2, ASC and GSDMD in the kidney among different groups. (D) The calpain activity of renal issues was measured by the relative fluorescence units (400/505 nm). (E) The cathepsin B activity of kidney issues was tested by the relative fluorescence units (400/505 nm). (F) Representative immunohistochemical micrographs from the kidney issues of different groups stained with Calpain 1, Calpain 2 and AIM2. ×400, bar = 50 μm. All data were presented as mean ± SEM (n = 3). NS, no significance; *p < 0.05 vs. sham group; **p < 0.01 vs. sham group; ***p < 0.001 vs. sham group; #p < 0.05 vs. IR group; ##p < 0.01 vs. IR group; ###p < 0.001 vs. IR group. CP, calpeptin; IR, ischemia/reperfusion; RFU, relative fluorescence units.
5). AMPK activation attenuates cancer-induced bone pain by reducing mitochondrial dysfunction-mediated neuroinflammation: AMPK activation attenuates bone cancer pain. ACTA BIOCHIMICA ET BIOPHYSICA SINICA (PubMed: 36971458) [IF=3.7]

Application: WB    Species: Rat    Sample: spinal cord

Figure 4 Effect of AICAR treatment on NLRP3, NLRP1, NLRC4, and AIM2 inflammasome components (A,C) Representative immunofluorescence staining images showing the expressions of NLRP3 and caspase-1 in the spinal dorsal horn of sham and CIBP rats. Scale bar: 20 μm. (B,D) Quantitative analysis of fluorescence intensity in (A) and (C). Data are expressed as the mean±SD ( n=3). * P

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.